Colorectal cancer

Score 7.8 = 7.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph1/Ph2NCT07915921 · Genfleet Therapeutics (Shanghai) Inc. · A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
• Ph1/Ph2NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
• Ph2NCT07133750 · Biotheus Inc. · PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Score 7.4 = 5.4 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 2 of 2 trials are Phase 2+.

• ESMO 2026 3530O (proffered paper) · Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial

• Ph2NCT07728019 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
• Ph3NCT07722494 · Innovent Biologics (Suzhou) Co. Ltd. · IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

Score 5.6 = 5.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07580339 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
• Ph2NCT07281768 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Score 5.5 = 5.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07809893 · Sun Yat-sen University · Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
• Ph3NCT07729605 · Sun Yat-sen University · FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

Score 5.4 = 5.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07789210 · Zhejiang University · A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases
• Ph3NCT07722494 · Innovent Biologics (Suzhou) Co. Ltd. · IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

Score 4.4 = 4.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph2NCT05969860 · Mayo Clinic · At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
• Ph2NCT06265285 · Mayo Clinic · Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
• Ph2NCT07285044 · Mayo Clinic · The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Score 4.3 = 4.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph3NCT06850090 · Shandong Cancer Hospital and Institute · Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
• Ph2NCT06778382 · Shandong Cancer Hospital and Institute · Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
• Ph3NCT06246344 · Shandong Cancer Hospital and Institute · Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Score 3.6 = 2.6 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph2NCT07595874 · City of Hope Medical Center · Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
• Ph1NCT07842965 · City of Hope Medical Center · CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial

Score 3.2 = 3 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph2NCT07551596 · National Cancer Institute (NCI) · Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
• Ph1NCT04704661 · National Cancer Institute (NCI) · Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Score 3.1 = 3 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph3NCT07271355 · City of Hope Medical Center · Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
• Ph1NCT04329494 · City of Hope Medical Center · PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06258525 · Cedars-Sinai Medical Center · SAMe in Prevention of Oxaliplatin-associated Liver Injury

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07668284 · University of Nebraska · COQ10 and Vitamin E for Off-Target Radiation Toxicity

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07292298 · University of Colorado, Denver · Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07621497 · Sun Yat-sen University · FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06057831 · AHS Cancer Control Alberta · PET/MRI in Rectal Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07433673 · Columbia University · Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07516210 · Centre hospitalier de l'Université de Montréal (CHUM) · Adaptive Radiotherapy for Safe Hypofractionation

Score 3 = 1 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 791RO (rapid oral) · Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study

• Ph1/Ph2NCT05691491 · National Cancer Institute (NCI) · Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07662031 · Washington University School of Medicine · Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07927998 · Memorial Sloan Kettering Cancer Center · A Study of Retifanlimab After Chemoradiation in People With Anal Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07913906 · University of Calgary · Alberta Cancer Exercise Dose in Colorectal Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07612007 · Mayo Clinic · HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07576725 · Fred Hutchinson Cancer Center · Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07847229 · Tao Zhang · A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07209215 · University of California, Davis · ctDNA-Informed Management of Early-Stage Rectal Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07691489 · Memorial Sloan Kettering Cancer Center · A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07877597 · Fudan University · Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07877597 · Fudan University · Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05686226 · Christian Hinrichs · E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
• Ph1/Ph2NCT05639972 · Christian Hinrichs · E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Score 2.8 = 1.8 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph1NCT07363408 · City of Hope Medical Center · Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
• Ph1/Ph2NCT05627635 · City of Hope Medical Center · FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
• Ph1/Ph2NCT05672316 · City of Hope Medical Center · Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07775209 · University of Vermont Medical Center · Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07594626 · Northwestern University · BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07765667 · Sixth Affiliated Hospital, Sun Yat-sen University · NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07765667 · Sixth Affiliated Hospital, Sun Yat-sen University · NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07819604 · Xijing Hospital · Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07277322 · Dan Feng · Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07735624 · Dana-Farber Cancer Institute · RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07720115 · M.D. Anderson Cancer Center · Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07636785 · VM Discovery, Inc. · A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07722754 · Guangdong Provincial People's Hospital · Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial